For the first time, doctors have used the results of a liquid biopsy test to detect and treat cancer in otherwise healthy people, according to a study unveiled this week in a leading journal and at a major oncology meeting. The data are a boon for proponents of liquid biopsy technology, and especially for the company commercializing one such test, Thrive Earlier Detection. But some outside experts caution that the tests still need more work to live up to their promise.

The new data show that the test successfully helped doctors at Geisinger Health System diagnose and treat some types of cancers that don’t currently have screening tests, like uterine and thyroid cancer, before people started reporting symptoms. As a result, it doubled the rate of cancers detected by screening rather than by patients reporting worrying symptoms. Normal, standard practice cancer screenings detected about 25% of the cases of cancer among study participants; when Thrive’s blood test was incorporated, too, that detection rate rose to 52.1%. The study is the first time liquid biopsies have been used with the explicit goal of guiding people’s medical care.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy